Search Results for "fexofenadine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fexofenadine. Results 1 to 4 of 4 total matches.
See also: Allegra
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
, hypertension,
nausea, vomiting, and urinary
retention
363.60
Fexofenadine –
Allegra Allergy, Children’s ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e55-7 doi:10.58347/tml.2025.1725b | Show Introduction Hide Introduction
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
― Use of an oral second-generation
H1-antihistamine, such as fexofenadine,
or an intranasal ...
The FDA has approved Dextenza (Ocular Therapeutix),
a dexamethasone ophthalmic insert, for
treatment of ocular itching associated with allergic
conjunctivitis. Dextenza was approved earlier for
treatment of ocular inflammation and pain following
ophthalmic surgery.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):45-6 doi:10.58347/tml.2023.1672b | Show Introduction Hide Introduction
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
,
such as fexofenadine, can be used in patients
with systemic allergies or to reduce the severity of
disease flares ...
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):70-2 doi:10.58347/tml.2023.1675d | Show Introduction Hide Introduction
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
Fexofenadine (Allegra, and others)
is nonsedating and does not cause CNS impairment,
even in higher-than ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction